Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
GigaGen
GigaGen develops innovative biotherapeutics, including oncology antibody drug combinations and hyperimmune gammaglobulin.
Sector
Subsector
Keywords
Location
total rounds
total raised
Aviceda Therapeutics
Aviceda Therapeutics is a biotech company developing drugs for treating glyco-immune diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Ophidion
Ophidion is a biotechnology company that uses a Trojan horse strategy to deliver therapeutics to targeted sites in the brain.
Sector
Subsector
Location
total rounds
total raised
Alethia BioTherapeutics
Alethia BioTherapeutics develops monoclonal antibody-based therapeutics for cancer-associated diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds1
Number of Funding Rounds
Money Raised
Their latest funding was raised on 09.09.2010. Their latest investor New Enterprise Associates. Their latest round Series A
New Enterprise Associates
NEA is a global venture capital firm that helps entrepreneurs build innovative businesses in technology and healthcare.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors1
Number of lead investors
Number of investors
New Enterprise Associates
NEA is a global venture capital firm that helps entrepreneurs build innovative businesses in technology and healthcare.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
David Parkinson
David Parkinson is acting CEO of Zyngenia, Inc., and a Venture Partner at New Enterprise Associates (NEA). From 2007 until 2012.Parkinson has served as a director of the Company since June 24, 2015 and has been employed full time as the President and Chief Executive Officer of the Company since January 7, 2016. Parkinson served as President and CEO of Nodality, a South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making. Prior to 2007, Parkinson was Senior Vice President of Oncology Research and Development at Biogen Idec 2006-2007, Vice President of Oncology Development at Amgen 2003-2006 and Vice President of Global Clinical Oncology Development at Novartis 1997-2003. Parkinson also worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as acting Associate Director of the Cancer Therapy Evaluation Program. Parkinson is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee, has also served on the FDA’s Science Board, and is a recipient of the FDA's Cody Medal. He has served on the National Cancer Policy Forum of the Institute of Medicine, as a board director for the Ontario Institute for Cancer Research, and is a past co-chair of the Cancer Steering Committee of the NIH Foundation Biomarkers Consortium. He currently serves as a Board Director for the Multiple Myeloma Research Foundation and has served as Chairperson of the American Association of Cancer Research (AACR) Finance and Audit Committee for the last 15 years. Parkinson was formerly a Director of Facet Biotech, Inc. and Ambit Biosciences, both public biopharma companies which were acquired by large pharma. He currently serves as Director on the Boards of Cerulean Pharma Inc., 3S Bio Inc. He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center, and has authored over 100 peer-reviewed publications.
current job
People
Founders2
Peter Kiener
Peter Kiener has deep experience in both biologics and immunotherapy, and is the former Chief Scientific Officer at Sucampo. Prior to joining Sucampo, he served as CSO of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates. Prior to Ambrx, Peter Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held leadership roles at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. He also worked on biologics for Bristol-Myers Squibb prior to his work at MedImmune. Peter Kiener has served on the scientific advisory boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation and as a member of the Board of Directors of Receptor BioLogix Inc., Synovex Corporation and Virdante Pharmaceuticals Inc. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. Peter Kiener earned a bachelor’s degree in chemistry from the University of Lancaster and a doctorate of philosophy in biochemistry from the University of Oxford.
current job
Peter Kiener
Carlos Barbas
Founder at Zyngenia Inc. Professor of Molecular Biology and Chemistry at The Scripps Research Institute.
current job
organization founded
Carlos Barbas